Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RG 7795

Drug Profile

RG 7795

Alternative Names: ANA 773; RG7795

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anadys Pharmaceuticals
  • Developer Anadys Pharmaceuticals; Roche
  • Class Antineoplastics; Antivirals; Small molecules
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C; Solid tumours

Most Recent Events

  • 01 Jul 2015 Phase-II clinical trials in Hepatitis B in Switzerland (PO)
  • 02 Feb 2012 Phase-I clinical trials in Hepatitis C in Netherlands (PO)
  • 02 Feb 2012 Anadys Pharmaceuticals terminates a phase IIa trial in Hepatitis C in Netherlands (ANA773-602; EudraCT2011-000728-14)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top